The brain in Down syndrome

Journal of Neural Transmission, Supplement

Volumn , Issue 61, 2001, Pages 247-261

  Seidl, R ^a   Cairns, N ^b   Lubec, G ^a  

^a UNIVERSITY OF VIENNA   (Austria)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID PRECURSOR PROTEIN; COPPER ZINC SUPEROXIDE DISMUTASE; PROTEIN S100B;

APOPTOSIS; BRAIN CELL; BRAIN REGION; CATECHOLAMINE NERVE CELL; CHOLINERGIC NERVE; CHROMOSOME 21; DEVELOPMENTAL DISORDER; DOWN SYNDROME; GENE EXPRESSION; GENE OVEREXPRESSION; GLIA CELL; HOMEOSTASIS; HUMAN; MENTAL DEFICIENCY; NERVE CELL DIFFERENTIATION; NERVE CONDUCTION; PRIORITY JOURNAL; REVIEW; SEROTONINERGIC NERVE CELL; BRAIN; PATHOLOGY; PATHOPHYSIOLOGY;

BRAIN; DOWN SYNDROME; HUMAN; SUPPORT, NON-U.S. GOV'T;

EID: 0035226525     PISSN: 03036995     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-7091-6262-0_20     Document Type: Review

References (90)

1. Acquati F, Accarino M, Nucci C, Fumagelli P, Jovine L, Ottolenghi S, Taramelli R (2000) The gene encoding DRAP (BACE2), a glycosylated transmembrane protein of the aspartic family, maps to Down critical region. FEBS Lett 468: 59-64
2. Anderson AJ, Stoltzner S, Lai F, Su J, Nixon RA (2000) Morphological and biochemical assessment of DNA damage and apoptosis in Down syndrome and Alzheimer disease, and effect of postmortem tissue archival on TUNEL. Neurobiol Aging 21: 511-524
3. Arai Y, Suzuki A, Mizuguchi, Takashima S (1997) Developmental and aging changes in the expression of amyloid precursor protein in Down syndrome brains. Brain Dev 19: 290-294
4. Armstrong RA (1996) Correlation between the morphology of diffuse and primitive beta-amyloid (A-beta) deposits and the frequency of associated cells in Down's syndrome. Neuropathol Appl Neurobiol 22: 527-530
5. Aylward EH, Li Q, Honeycutt NA (1999) MRI volumes of the hippocampus and amygdala in adults with Down's syndrome with and without dementia. Am J Psychiatry 156: 564-568
6. Azmitia EC (1999) Serotonin neurons, neuroplasticity, and homeostasis of neural tissue. Neuropsychopharm 21: 33S-45S
7. Bazelon M, Paine RS, Coeiw VA, Hunt P, Houck JC, Mahanand D (1967) Reversal of hypotonia in infants with Down's syndrome by administration of 5-hydroxytryptophan. Lancet 1: 1130-1133
8. Becker LE, Armstrong DL, Chan F (1986) Dentritic atrophy in children with Down's Syndrome. Ann Neurol 20: 520-526
9. Becker LE, Mito T, Takashima S, Onodera K (1991) Growth and development of the brain in Down syndrome. Prog Clin Biol Res 373: 133-152
10. Bennet BD, Babu-Khan S, Loeloff R, Louis JC, Curran Eileen, Citrol M, Vassar R (2000) Expression analysis of BACE2 in brain and peripheral tissues. J Biol Chem 275: 20647-20651
11. Busciglio J, Yankner BA (1995) Apoptosis and increased generation of reactive oxygen species in Down Syndrome. Nature 378: 776-779
12. Cairns NJ (1999) Neuropathology. J Neural Transm [Suppl] 57: 61-74
13. Castagne V, Gautschi M, Lefevre K, Posada A, Clarke PGH (1999) Relationships between neuronal death and the cellular redox status. Focus on the developing nervous system. Progr Neurobiol 59: 397-423
14. Celi FS, Cohen MM, Antonarakis SE, Wertheimer E, Roth J, Shuldiner AR (1994) Determination of gene dosage by a quantitative adaptation of the polymerase chain reaction (gd-PCR): rapid detection of deletions and duplications of gene sequences. Genomics 21: 304-310
15. Coleman M (1971) Infantile spasms associated with 5-hydroxytryptophan administered in patients with Down's syndrome. Neurol 21: 911
16. De Haan JB, Wolvetang EJ, Christiano F, Ianello R, Bladier C, Kelner MJ, Kola I (1997) Reactive oxygen species and their contribution to pathology in Down syndrome. Adv Pharmacol 38: 379-402
17. DelaMonte SM, Sohn YK, Ganju N, Wands JR (1998) p53-and CD95-associated apoptosis in neurodegenerative diseases. Lab Invest 78: 401-411
18. Dragovich T, Rudin CM, Thompson CB (1998) Signal transduction pathways that regulate cell survival and cell death. Oncogene 17: 3207-3213
19. Dringenberg HC (2000) Alzheimer's disease: more than a cholinergic disorder - evidence that cholinergic-monoaminergic interactions contribute to EEG slowing and dementia. Behav Brain Res 115: 235-249
20. Egensperger R, Weggen S, Ida N, Multhaup G, Schnabel R, Beyreuther K, Bayer TA (1999) Reverse relationship between β-amyloid precursor protein and β-amyloid peptide plaques in Down's syndrome versus sporadic/familial Alzheimer's disease. Acta Neuropathol 97: 113-118
21. Epstein CJ (1995) Down Syndrome (Trisomy 21). In: Scriver SR, Beaudet AL, Sly WS, Valle D (eds) The metabolic and molecular bases of inherited disease. McGraw-Hill, New York, pp 749-794
22. Farzan M, Schnitzler CE, Vasilieva N, Leung N, Choe H (2000) BACE2, a β-secretase homolog, cleaves at the β site and within the amyloid-β region of the amyloid-β precursor protein. PNAS 97: 9712-9717
23. Friedlich AL, Butcher LL (1994) Involvement of free oxygen radicals in β-amyloidosis: an hypothesis. Neurobiol Aging 15: 443-455
24. Gedye A (1990) Dietary increase in serotonin reduces self-injurious behaviour in a Down's syndrome adult. J Ment Defic Res 34: 195
25. Gedye A (1991) Serotonergic treatment for aggression in a Down's syndrome adult showing signs of Alzheimer's disease. J Ment Defic 35: 247-258
26. Geldmacher DS, Lerner AJ, Voci JM, Noelker EA, Somple LC, Whitehouse PJ (1997) Treatment of functional decline in adults with Down syndrome using selective serotonin-reuptake inhibitor drugs. J Geriatr Psychiat Neurol 10: 99-104
27. Giaccone G, Tagliavini F, Linoli G, Bouras C, Frigerio L, Frangione B, Bugiano O (1989) Down patients: extracellular preamyloid deposits precede neuritic degeneration and senile plaques. Neurosci Lett 97: 232-238
28. Godridge H, Reynolds GP, Czudek C, Calcutt NA, Benton M (1987) Alzheimer-like neurotransmitter deficits in adult Down's syndrome brain tissue. J Neurol Neurosurg Psychiatry 50: 775-778
29. Griffin WST, Sheng JG, McKenzie LE, Royston MC, Gentleman SM, Brumback RA, Cork LC, Del Bigio MR, Roberts GW, Mrak RE (1998) Life-long overexpression pf S100β in Down's syndrome: implications for Alzheimer pathogenesis. Neurobiol Aging 19: 401-405
30. Gulleserian T, Seidl R, Hardmeier R, Cairns N, Lubec G (2001) Superoxide dismutase SOD1, encoded on chromosome 21, but not SOD2 is overexpressed in brains of patients with Down syndrome. J Invest Med 49: 41-46
31. Haxby JV (1989) Neuropsychological evaluation of adults with Down's syndrome: patterns of selective impairment in nondemented old adults. J Ment Defic Res 33: 193-197
32. Haxby JV, Schapiro MB (1992) Longitudinal study of neuropsychological functions in older adults with Down syndrome. In: Epstein C, Nadel L (eds) Down syndrome and Alzheimer disease. Wiley Liss, New York, pp 35-50
33. Herdegen T (1996) Jun, Fos, and CREB/ATF transcription factors in the brain: control of gene expression under normal and pathophysiological conditions. Neuroscientist 2: 153-161
34. Higgins LS, Catalano R, Quon D, Cordell B (1993) Transgenic mice expressing human βAPP751, but not mice expressing βAPP695, display early Alzheimer's disease-like histopathology. Ann NY Acad Sci 695: 224-227
35. Howlett DR, Simmons DL, Dingwall C, Christie G (2000) In search of an enzyme: the β-secretase of Alzheimer's disease is an aspartic proteinase. Trends Neurosci 23: 565-570
36. Jacobs B, Fornal C (1995) Serotonin and behavior, a general hypothesis. In: Bloom F, Kupfer D (eds) Psychopharmacology: the fourth generation of progess. Raven Press, New York, pp 461-469
37. Kishnani PS, Sullivan JA, Walter BK, Spiridigliozzi GA, Doraiswamy PM, Krishnan KRR (1999) Cholinergic therapy for Down's syndrome. Lancet 353: 1064-1065
38. Kroemer G (1997) The proto-oncogene Bcl-2 and its role in regulating apoptosis. Nature Med 3: 614-620
39. Labudova O, Krapfenbauer K, Moenkemann H, Rink H, Kitzmüller E, Cairns N, Lubec G (1998) Decreased transcription factor JunD in brains of patients with Down syndrome. Neurosci Lett 252: 159-162
40. Lauder JM (1993) Neurotransmitters as growth regulatory signals: role of receptors and second messengers. Trends Neurosci 16: 233-240
41. Lemere CA, Blustzjan JK, Yamaguchi H, Wisniewski T, Saido TC, Selkoe DJ (1996) Sequence of deposition of heterogenous amyloid-β-peptides and ApoE in Down syndrome: implications for initial events in amyloid plaque formation. Neurobiol Dis 3: 16-32
42. Lin X, Koelsch G, Wu S, Downs D, Dashti A, Tang J (2000) Human aspartic protease memapsin 2 cleaves the β-secretase site of β-amyloid precursor protein. PNAS 97: 1456-1460
43. β - peptide precursor. Nature Med 6: 397-404
44. Mann DA (1988) The pathological association between Down syndrome and Alzheimer disease. Mech Ageing Dev 43: 99-136
45. Mann DM, Yates PO, Marcyniuk B, Rawndra CR (1985) Pathological evidence for neurotransmitter deficits in Down's syndrome of middle age. J Ment Defic Res 29: 125-135
46. Mann DMA, Yates PO (1986) Neurotransmitter deficits in Alzheimer's disease and in other dementing disorders. Hum Neurobiol 5: 147-158
47. Mann DMA, Royston MC, Ravindra CR (1990) Some morphological observations on the brains of patients with Down's syndrome: their relationship to age and dementia. J Neurol Sci 99: 153
48. Marks A, O'Hanlon D, Lei M, Percy ME, Becker LE (1996) Accumulation of S100β mRNA and protein in cerebellum during infancy in Down syndrome and control subjects. Mol Brain Res 36: 343-348
49. Masumura M, Hata R, Nishimura I, Uetsuki T, Sawada T, Yoshikawa K (2000) Caspase-3 activation and inflammatory responses in rat hippocampus inoculated with a recombinant adenovirus expressing the Alzheimer amyloid precursor protein. Mol Brain Res 80: 219-227
50. Mehler MF, Gokhan S (2000) Mechanisms underlying neural cell death in neurodegenerative diseases: alterations of a developmentally-mediated cellular rheostat. Trends Neurosci 23: 599-605
51. Miranda S, Opazo C, Larrondo LF, Munoz FJ, Ruiz F, Leighton F, Inestrosa NC (2000) The role of oxidative stress in the toxicity induced by amyloid β-peptide in Alzheimer's disease. Progr Neurobiol 62: 633-648
52. Nagy Z, Esiri MM (1997) Apoptosis-related protein expression in the hippocampus in Alzheimer's disease. Neurobiol Aging 18: 565-571
53. Neve RL, McPhie DL, Chen Y (2000) Alzheimer's disease: a dysfunction of amyloid precursor protein. Brain Res 886: 54-66
54. Owen-Schaub LB, Zhang W, Cusack JC (1995) Wild-type human p53 and a temperature-sensitive mutant induce Fas/APO-1 expression. Mol Cell Biol 15: 3032-3040
55. Oyama F, Cairns NJ, Shimada H, Oyama R, Titani K, Ihara Y (1994) Down' syndrome: upregulation of β-amyloid protein precursor and τ mRNAs and their defective coordination. J Neurochem 62: 1062-1066
56. Pangalos C, Theophile D, Sinet PM, Marks A, Stamboulieh-Abazis D, Chettouch Z, Prieur M, Verellen C, Rethore M-O, Lejeune J, Delaber J-M (1992) No significant effect of monosomy for distal 21q22.3 on the Down syndrome phenotype in 'mirror' duplications of chromosome 21. Am J Hum Genet 51: 1240-1250
57. Pellegrini L, Passer BJ, Tabaton M, Ganjei JK, D'Adamio L (1999) Alternative, nonsecretase processing of Alzheimer's β-amyloid precursor protein during apoptosis by caspase-6 and -8. J Biol Chem 274: 21011-21016
58. Pietrini P, Alexander GE, Furey ML, Hampel H, Guazelli M (2000) The neurometabolic landscape of cognitive decline: in vivo studies with positron emission tomography in Alzheimer's disease. Int J Psychophysiol 37: 87-98
59. Podlisny MB, Lee G, Selkoe DJ (1987) Gene dosage of the amyloid beta precursor protein in Alzheimer's disease. Science 238(4827): 669-671
60. Prasher VP, Farrer MJ, Kessling AM, Fisher EMC, West RJ, Barber PC, Butler (1998) Molecular mapping of Alzheimer-type dementia in Down's syndrome. Ann Neurol 43: 380-383
61. NTR and Fas? Corr Opin Neurobiol 10: 111-117
62. Reynolds GP, Warner CEJ (1988) Amino acid neurotransmitter deficits in adult Down's syndrome brain tissue. Neurosci Lett 94: 224-227
63. Risser D, Lubec G, Cairns N, Herrera-Marschitz M (1997) Excitatory amino acids and monoamines in parahippocampal gyrus and frontal cortical pole of adults with Down syndrome. Life Sci 60: 1231-1237
64. Roßner S, Ueberham U, Schliebs R, Schliebs R, Perez-Polo JR, Bigl V (1998) The regulation of amyloid precursor protein metabolism by cholinergic mechanisms and neurotrophin receptor signaling. Progr Neurobiol 56: 541-569
65. Rumble B, Retallack R, Hilbich C, Simms G, Multhaup G, Martins R, Hockey A, Montgomery P, Beyreuther K, Masters CL (1989) Amyloid A4 protein and its precursor in Down's syndrome and Alzheimer's disease. N Engl J Med 320: 1446-1452
66. Saunders AJ, Kim T-W, Tanzi RE, Fan W, Bennet BD, Babu-Khan S, Luo Y, Louis J-C, McCaleb M, Citron M, Vassar R, Richards WG (1999) BACE maps to chromosome 11 and a BACE homolog, BACE2, reside in the obligate Down syndrome region of chromosome 21. Science 286: 1255-1256
67. Sawa A, Oyama F, Cairns NJ, Amano N, Matsushita M (1997) Aberrant expression of bcl-2 gene family in Down's syndrome brains. Mol Brain Res 48: 53-59
68. Schapiro MB, Haxby JV, Grady CL (1992) Nature of mental retardation and dementia in Down syndrome: study with PET, CT, and neuropsychology. Neurobiol Aging 13: 723-734
69. Seidl R, Fang-Kircher S, Bidmon B, Cairns N, Lubec G (1999) Apoptosis-associated proteins p53 and APO-1/Fas (CD95) in brains of adult patients with Down syndrome. Neurosci Lett 260: 9-12
70. Seidl R, Kaehler ST, Prast H, Singewald N, Cairns N, Gratzer M, Lubec G (1999) Serotonin (5-HT) in brains of adult patients with Down syndrome. J Neural Transm [Suppl] 57: 221-232
71. Seidl R, Cairns N, Singewald N, Kaehler ST, Lubec G (2001) Cortical GABA deficit in Alzheimer's disease but not in adult Down syndrome. Naunyn Schmiedebergs Arch Pharmacol 363: 139-145
72. + astrocytes with neurofibrillary tangle stage. J Neuropathol Exp Neurol 56: 285-290
73. Sheng JG, Mrak RE, Bales KR (2000) Overexpression of the neuritotrophic cytokine S100β precedes the appearance of neuritic beta-amyloid plaques in APPV717F mice. J Neurochem 74: 295-301
74. Smith MA, Perry G (1998) What are the facts and artifacts of the pathogenesis and etiology of Alzheimer disease. J Chem Neuroanat 16: 35-41
75. St. Clair DF, Blackwood D (1985) Premature senility in Down's syndrome. Lancet Jul 6:34
76. Stadelmann C, Deckwerth TL, Srinivasan A, Bancher C, Brück W, Jellinger K, Lassmann H (1999) Activation of caspase-3 in single neurons and autophagic granules of granulovacuolar degeneration in Alzheimer's disease. Evidence for apoptotic cell death. Am J Pathol 155: 1459-1466
77. Stoltzner S, Grenfell TJ, Mori C, Wisniewski KE, Wisniewski TM, Selkoe DJ, Lemere CA (2000) Temporal accrual of complement proteins in amyloid plaques in Down's syndrome with Alzheimer's disease. Am J Pathol 156: 489-499
78. The chromosome 21 mapping and sequencing consortium (2000) The DNA sequence of human chromosome 21. Nature 405: 311-319
79. Teller JK, Russo C, DeBusk LM, Angelini G, Zaccheo D, Dagna-Bricarelli F, Scartezzini P, Bertolini S, Mann DM, Tabaton M, Gambetti P (1996) Presence of soluble amyloid β-peptide precedes amyloid plaque formation in Down's syndrome. Nat Med 2: 31-32
80. Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, Hansen LA, Katzman R (1991) Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol 30: 572-580
81. Vickers JC, Dickson TC, Adlard PA Saunders HL, King CE, McCormack G (2000) The cause of neuronal degeneration in Alzheimer's disease. Progr Neurobiol 60: 139-165
82. Warren AC, Holroyd S, Folstein P (1989) Major depression in Down's syndrome. Br J Psychiatry 155: 202-207
83. Weise P, Koch R, Shaw KNF, Rosenfeld MJ (1974) The use of 5-HTP in the treatment of Down's syndrome. Pediatr 54: 165-167
84. Whitaker-Azmitia PM, Wingate M, Borella A, Gerlai R, Roder J, Azmitia EC (1997) Transgenic mice overexpressing the neurotrophic factor S-100 beta show neuronal cytoskeletal and behavioral signs of altered aging processes: implications for Alzheimer's disease and Down's syndrome. Brain Res 776: 51-60
85. Wisniewski KE, Kida E (1994) Abnormal neurogenesis and synaptogenesis in Down syndrome brain. Dev Brain Dysfunct 7: 289-301
86. Wisniewski KE, Wisniewski HM, Wen GY (1985) Occurrence of neuropathological changes and dementia of Alzheimer's disease in Down syndrome. Ann Neurol 17: 278-282
87. Yates CM, Simpson J, Maloney AFJ, Gordon A, Reid AH (1980) Alzheimer-like cholinergic deficiency in Down syndrome. Lancet 2(8201): 979
88. Yates CM, Simpson J, Gordon A, Maloney AFJ, Allison Y, Ritchie IM, Urquhart A (1983) Catecholamines and cholinergic enzymes in pre-senile and senile Alzheimer-type dementia and Down's syndrome. Brain Res 280: 119-126
89. Yates CM, Simpson J, Gordon A (1986) Regional brain 5-hydroxytryptamine levels are reduced in senile Down's syndrome as in Alzheimer's disease. Neurosci Lett 65: 189-192
90. Yoshida H, Kong Y-Y, Yoshida R (1998) Apaf1 is required for mitochondrial pathways of apoptosis and brain development. Cell 94: 739-750